310 related articles for article (PubMed ID: 21596526)
1. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.
Lemaire S; Van Bambeke F; Tulkens PM
Int J Antimicrob Agents; 2011 Jul; 38(1):52-9. PubMed ID: 21596526
[TBL] [Abstract][Full Text] [Related]
2. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes.
Idelevich EA; Kriegeskorte A; Stubbings W; Kahl BC; Peters G; Becker K
J Antimicrob Chemother; 2011 Dec; 66(12):2809-13. PubMed ID: 21948963
[TBL] [Abstract][Full Text] [Related]
4. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
5. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Vallet CM; Marquez B; Ngabirano E; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Int J Antimicrob Agents; 2011 Sep; 38(3):249-56. PubMed ID: 21764262
[TBL] [Abstract][Full Text] [Related]
6. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus.
Seral C; Carryn S; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2003 May; 51(5):1167-73. PubMed ID: 12697643
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections.
Baudoux P; Bles N; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2007 Feb; 59(2):246-53. PubMed ID: 17220162
[TBL] [Abstract][Full Text] [Related]
8. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.
Lemaire S; Van Bambeke F; Tulkens PM
Antimicrob Agents Chemother; 2009 Sep; 53(9):3734-43. PubMed ID: 19564365
[TBL] [Abstract][Full Text] [Related]
9. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Van de Velde S; Nguyen HA; Van Bambeke F; Tulkens PM; Grellet J; Dubois V; Quentin C; Saux MC
J Antimicrob Chemother; 2008 Sep; 62(3):518-21. PubMed ID: 18544595
[TBL] [Abstract][Full Text] [Related]
10. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin.
Imbuluzqueta E; Lemaire S; Gamazo C; Elizondo E; Ventosa N; Veciana J; Van Bambeke F; Blanco-Prieto MJ
J Antimicrob Chemother; 2012 Sep; 67(9):2158-64. PubMed ID: 22615297
[TBL] [Abstract][Full Text] [Related]
12. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
Lemaire S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
J Antimicrob Chemother; 2005 Jun; 55(6):897-904. PubMed ID: 15860552
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.
Lemaire S; Van Bambeke F; Appelbaum PC; Tulkens PM
J Antimicrob Chemother; 2009 Nov; 64(5):1035-43. PubMed ID: 19759040
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.
Furneri PM; Bazzano M; Campo L; Cesana M; Tempera G
Chemotherapy; 1994; 40(2):104-8. PubMed ID: 8131632
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
Lemaire S; Kosowska-Shick K; Appelbaum PC; Verween G; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2010 Jun; 54(6):2549-59. PubMed ID: 20385852
[TBL] [Abstract][Full Text] [Related]
17. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.
Lismond A; Tulkens PM; Mingeot-Leclercq MP; Courvalin P; Van Bambeke F
Antimicrob Agents Chemother; 2008 Sep; 52(9):3040-6. PubMed ID: 18573933
[TBL] [Abstract][Full Text] [Related]
18. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
Almahmoud I; Kay E; Schneider D; Maurin M
J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
[TBL] [Abstract][Full Text] [Related]
19. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.
Stubbings W; Leow P; Yong GC; Goh F; Körber-Irrgang B; Kresken M; Endermann R; Labischinski H
Antimicrob Agents Chemother; 2011 Sep; 55(9):4394-7. PubMed ID: 21709094
[TBL] [Abstract][Full Text] [Related]
20. Influence of pH on the activity of finafloxacin against extracellular and intracellular Burkholderia thailandensis, Yersinia pseudotuberculosis and Francisella philomiragia and on its cellular pharmacokinetics in THP-1 monocytes.
Chalhoub H; Harding SV; Tulkens PM; Van Bambeke F
Clin Microbiol Infect; 2020 Sep; 26(9):1254.e1-1254.e8. PubMed ID: 31404671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
